Amicus Therapeutics, Inc. Earnings

Amicus Therapeutics, Inc.’s revenue jumped 13.45% since last year same period to $125.25Mn in the Q1 2025. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated -16.34% fall in its revenue since last 3-months.

Amicus Therapeutics, Inc.’s net profit jumped 55.21% since last year same period to $-21.69Mn in the Q1 2025. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated -247.13% fall in its net profits since last 3-months.

Amicus Therapeutics, Inc.’s net profit margin jumped 60.52% since last year same period to -17.31% in the Q1 2025. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated -275.86% fall in its net profit margins since last 3-months.

Amicus Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.02 - a 119.29% jump from last quarter’s estimates.

Amicus Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 0.02.

Amicus Therapeutics, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Amicus Therapeutics, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.